BRPI0716983A2 - Mólecula de ligação isolada, molécula de ácido nucleico, composição farmacêutica, e, uso de uma molécula de ligação - Google Patents

Mólecula de ligação isolada, molécula de ácido nucleico, composição farmacêutica, e, uso de uma molécula de ligação

Info

Publication number
BRPI0716983A2
BRPI0716983A2 BRPI0716983-3A2A BRPI0716983A BRPI0716983A2 BR PI0716983 A2 BRPI0716983 A2 BR PI0716983A2 BR PI0716983 A BRPI0716983 A BR PI0716983A BR PI0716983 A2 BRPI0716983 A2 BR PI0716983A2
Authority
BR
Brazil
Prior art keywords
mollecle
connection
nucleic acid
pharmaceutical composition
isolated
Prior art date
Application number
BRPI0716983-3A2A
Other languages
English (en)
Inventor
Den Brink Edward Norbert Van
Kruif Cornelis Adriaan De
Mark Throsby
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Priority claimed from PCT/EP2007/059356 external-priority patent/WO2008028946A2/en
Publication of BRPI0716983A2 publication Critical patent/BRPI0716983A2/pt
Publication of BRPI0716983B1 publication Critical patent/BRPI0716983B1/pt
Publication of BRPI0716983B8 publication Critical patent/BRPI0716983B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0716983A 2006-09-07 2007-09-06 anticorpo humano isolado, ou fragmento de ligação ao antígeno do mesmo,capaz de reconhecer e se ligar a um epítopo da subunidade ha2 da proteína hemaglutinina de influenza (ha), molécula de ácido nucleico e composição farmacêutica. BRPI0716983B8 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US84293006P 2006-09-07 2006-09-07
US60/842930 2006-09-07
EP06120316 2006-09-07
EP06120316.2 2006-09-07
EP06120644.7 2006-09-14
EP06120644 2006-09-14
EP06125107.0 2006-11-30
EP06125107 2006-11-30
EP07111235.3 2007-06-28
EP07111235 2007-06-28
PCT/EP2007/059356 WO2008028946A2 (en) 2006-09-07 2007-09-06 Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0716983A2 true BRPI0716983A2 (pt) 2013-10-15
BRPI0716983B1 BRPI0716983B1 (pt) 2019-03-26
BRPI0716983B8 BRPI0716983B8 (pt) 2021-05-25

Family

ID=45468077

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716983A BRPI0716983B8 (pt) 2006-09-07 2007-09-06 anticorpo humano isolado, ou fragmento de ligação ao antígeno do mesmo,capaz de reconhecer e se ligar a um epítopo da subunidade ha2 da proteína hemaglutinina de influenza (ha), molécula de ácido nucleico e composição farmacêutica.

Country Status (11)

Country Link
EP (5) EP2455398B1 (pt)
BR (1) BRPI0716983B8 (pt)
DK (5) DK2455399T3 (pt)
ES (1) ES2402217T3 (pt)
MX (1) MX343198B (pt)
MY (1) MY165458A (pt)
NZ (1) NZ574581A (pt)
PT (1) PT2059532E (pt)
RS (1) RS52688B (pt)
SG (2) SG174773A1 (pt)
SI (1) SI2059532T1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110028578B (zh) * 2019-03-12 2021-05-11 中国科学院武汉病毒研究所 广谱抗h7流感病毒的中和性人源单克隆抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4625015A (en) * 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU4474497A (en) 1996-10-08 1998-05-05 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
ATE447617T1 (de) 1999-04-15 2009-11-15 Crucell Holland Bv Verwendung von rekombinanten proteinen in menschlichen zellen
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
NZ529465A (en) 2001-06-15 2005-05-27 Crucell Holland B Chimaeric phages

Also Published As

Publication number Publication date
SG174773A1 (en) 2011-10-28
EP2450378B1 (en) 2015-11-04
EP2455398B1 (en) 2015-11-18
EP2450376A2 (en) 2012-05-09
EP2450376A3 (en) 2012-08-01
MY165458A (en) 2018-03-22
EP2455399B1 (en) 2015-11-04
DK2450379T3 (da) 2016-02-08
EP2455398A2 (en) 2012-05-23
EP2450376B1 (en) 2018-02-28
ES2402217T3 (es) 2013-04-29
PT2059532E (pt) 2013-03-07
SI2059532T1 (sl) 2013-04-30
MX343198B (es) 2016-10-11
BRPI0716983B8 (pt) 2021-05-25
DK2450378T3 (da) 2016-02-01
BRPI0716983B1 (pt) 2019-03-26
DK2455398T3 (da) 2016-02-08
EP2455399A3 (en) 2012-05-30
NZ574581A (en) 2012-02-24
EP2455399A2 (en) 2012-05-23
SG10201607410TA (en) 2016-10-28
EP2450379A1 (en) 2012-05-09
RS52688B (en) 2013-08-30
EP2455398A3 (en) 2012-05-30
DK2059532T3 (da) 2013-03-18
EP2450379B1 (en) 2015-11-04
EP2450378A1 (en) 2012-05-09
DK2455399T3 (da) 2016-01-25

Similar Documents

Publication Publication Date Title
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0813770A2 (pt) Composição, e, uso de uma composição
RU2398586C3 (ru) Фармацевтическая композиция
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0817265A2 (pt) Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
NO20090578A (no) Farmasøytisk sammensetning inneholdende en tetrahydrofolsyre
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0720234A2 (pt) Composição farmacêutica
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0719398A2 (pt) Composição farmacêutica.
BRPI0719394A2 (pt) Preparação medicinal sólida
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2738 DE 27-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.